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Local recurrenceBackground and purpose: Early detection of local recurrences following stereotactic ablative radiotherapy
(SABR) for lung cancer may allow for curative salvage treatment, but recurrence can be difﬁcult to distin-
guish from ﬁbrosis. We studied the clinical performance of CT imaging high-risk features (HRFs) for
detecting local recurrence.
Materials and methods: Patients treated with SABR for early stage lung cancer between 2003 and 2012
who developed pathology-proven local recurrence (n = 12) were matched 1:2 to patients without recur-
rences (n = 24), based on baseline factors. Serial CT images were assessed by blinded radiation oncolo-
gists. Previously reported HRFs were (1) enlarging opacity at primary site; (2) sequential enlarging
opacity; (3) enlarging opacity after 12-months; (4) bulging margin; (5) loss of linear margin and (6)
air bronchogram loss.
Results: All HRFs were signiﬁcantly associated with local recurrence (p < 0.01), and one new HRF was
identiﬁed: cranio-caudal growth (p < 0.001). The best individual predictor of local recurrence was opacity
enlargement after 12-months (100% sensitivity, 83% speciﬁcity, p < 0.001). The odds of recurrence
increased 4-fold for each additional HRF detected. The presence ofP3 HRFs was highly sensitive and spe-
ciﬁc for recurrence (both >90%).
Conclusion: The systematic assessment of post-SABR CT images for HRFs enables the accurate prediction
of local recurrence.
 2013 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 109 (2013) 51–57Over the last decade, stereotactic ablative radiotherapy (SABR,
also referred to as SBRT) has been rapidly adopted into clinical
practice and has become the preferred treatment for early stage
non-small cell lung cancer (NSCLC) patients with medically inoper-
able tumors [1,2]. Single-institution, population-based and Mar-
kov-modeling studies have shown treatment outcomes after the
implementation of SABR to be comparable to that of surgery, the
historical gold-standard treatment [2–5]. SABR has also been
increasingly evaluated in the operable patient population, with
favorable outcomes [6,7]. As these ﬁtter patients are more likely
to be eligible for salvage treatments, appropriate follow-up for
the earliest possible detection of local recurrence is of paramount
importance.
Due to the high biologic doses delivered with SABR, the vast
majority of patients develop benign post-treatment ﬁbrosis within
2 years post-treatment [8,9]. Although local recurrences after SABR
for early stage NSCLC are uncommon when effective schemes withhigh biological doses are applied, the majority of these manifest
within the ﬁrst 2 years of treatment [3,10]. A failure to distinguish
between the appearance of recurrence and benign lung ﬁbrosis
may lead to unnecessary imaging, invasive testing, delay in salvage
or inappropriate salvage therapy.
An evidence-based approach for choice of imaging modality
during follow-up, and for the distinction of recurrence from ﬁbro-
sis after SABR, is lacking. Current imaging follow-up relies mainly
on CT imaging, with the role of FDG-PET/CT being unclear. Several
previous studies, including a systematic review, have identiﬁed
CT-based ‘‘high-risk features’’ (HRFs), which could distinguish
recurrence from ﬁbrosis [11]. However, these studies have not
been validated, and the sensitivity and speciﬁcity of these features
are unknown. Previous studies have been limited by a lack of
pathology-proven recurrences, due to both the infrequency of
recurrence and the lack of biopsy conﬁrmation in the frail patient
population traditionally treated with SABR. In addition, several
studies have included patients classiﬁed as having recurrence
based only on CT ﬁndings (without pathology), which likely over-
estimates the performance of CT, since CT is used to both deﬁne
and predict recurrence. The goals of the present study were to val-
idate the previously reported HRFs of recurrence, to identify and
52 Detecting recurrence after lung SABRtest possible novel features, to determine the sensitivity and spec-
iﬁcity of each feature in predicting recurrence, and to estimate the
increase in recurrence risk as additional HRFs are detected in an
individual patient.Methods
Patient population and treatment
Details of patients treated with SABR for early stage lung cancer
at the VU University Medical Center (VUmc) between April 2003
and July 2012 were retrieved from a prospective database. In the
Netherlands, retrospective studies of patient data, such as this
study, do not fall under the scope of the Medical Research Involv-
ing Human Subjects Act; this study is thus exempt from medical
ethics review. Patients with synchronous lung tumors were ex-
cluded from our study. Patients were treated to a dose of 54–
60 Gy prescribed to the 80% isodose in 3–8 risk-adapted fractions,
based on tumor size and location [12]. Radiation treatment plan-
ning and delivery techniques have been previously reported [12].
A follow-up CT chest with contrast enhancement (2.5–5 mm slice
thickness) was obtained at 3, 6 and 12 months, and annually
thereafter. More frequent CT imaging was obtained in cases of sus-
pected recurrence. FDG-PET scanning was not performed routinely
during follow-up, but only when disease recurrence was sus-
pected, in patients who were considered to be candidates for sal-
vage therapy.Deﬁnition of local recurrence
Local recurrence was deﬁned radiologically as a growing lesion
within the involved lobe on sequential follow-up scans that could
not clearly be attributable to lung ﬁbrosis, as previously described
[6]. During this time period, 31 patients were classiﬁed by a multi-
disciplinary tumor board as having local recurrence based on sus-
picious radiologic ﬁndings. Of these, 12 had pathology-proven local
recurrences and were matched 1:2 to patients without recurrence
(n = 24), from a group of 507 potential matches, according to base-
line factors. Patients were matched using a manual method, select-
ing matched controls based on the following factors: tumor
location (peripheral vs. central), fractionation (3, 5 or 8 fractions)
and PTV size (within 10%). All patients without recurrence were re-
quired to have available follow-up CT images at time intervals and
duration comparable to their matched recurrence counterparts.Image analysis
CT images were assessed for the presence of benign and HRFs
previously reported in the literature [8,13–16]. Benign changes
are subdivided into acute (within 6 months after treatment) and
late changes (beyond 6 months post-treatment). Acute changes in-
clude diffuse consolidation, patchy consolidation, diffuse ground
glass opacities (GGO), and patchy GGO; late changes include a
modiﬁed conventional pattern (deﬁned as volume loss, traction
bronchiectasis, and consolidation similar to changes after conven-
tional radiotherapy, but less extensive [8]), mass-like ﬁbrosis, and
scar-like ﬁbrosis). High-risk CT features have been previously re-
ported by Kato, Takeda, and Matsuo et al. [14–16]. The HRFs as-
sessed were (1) enlarging opacity at the primary site; (2)
sequential enlarging opacity; (3) enlarging opacity after
12 months; (4) bulging margin; (5) loss of linear margin and (6)
loss of air bronchograms (including partial loss). Enlarging opacity
was assessed according to RECIST 1.1 criteria [17]; speciﬁcally, size
was measured on axial slices as recommended, and any growth in
the transverse plane was recorded.Scoring was performed by blinded observers, viewing anony-
mized images projected onto a large screen. For reference, scorers
were provided with representative images and detailed descrip-
tions of benign and high-risk features. A minimum of two radiation
oncologists assessed scans for both high risk and benign features,
and any discrepancies were resolved by consensus or consultation
with an additional scorer if necessary. For each patient, the corre-
sponding baseline pre-treatment planning 4D-CT and radiotherapy
plan were available for review, and all follow-up images were then
displayed in sequential order, with all viewing options and win-
dow/level settings used in clinical practice available. Size measure-
ments were made using standard lung window settings. Areas of
ground glass opaciﬁcation were not included in the measurements.
Judges remained blinded to the status of the patient with respect to
recurrence.
Three new potential HRFs were investigated, namely (1) new
axial growth after complete response (2) cranio-caudal growth
(P5 mm andP20%) and (3) ratio of cranio-caudal growth to axial
growth.Data analysis
Descriptive statistics were generated for the presence of each of
the radiographic changes, stratiﬁed by recurrence/non-recurrence
and compared using the Chi-square test (or Fisher’s exact test
where appropriate). Sensitivity/speciﬁcity for each individual
high-risk feature was calculated, along with the sensitivity and
speciﬁcity for each additional cumulative high-risk feature (dichot-
omous cut-points, range: 0–7). Positive- and negative-predictive
values (PPV and NPV) are not reported, since they are dependent
on the prevalence of the outcome. In this 1:2 matched cohort,
PPV would be overestimated and NPV underestimated, relative to
an actual clinical scenario where recurrence is less common [18].
Univariable logistic regression models were constructed to identify
factors associated with recurrence. Since the study uses a matched
study design, adjusted odds ratios were computed by stratifying
for patient matching. All statistical analysis was performed using
SAS (version 9.2), using two-sided statistical testing at the 0.05 sig-
niﬁcance level.Results
Baseline characteristics of all 36 patients are summarized in
Table 1. Patients were well-matched in the recurrence and non-
recurrence groups. The median age at diagnosis was 68 years and
median post-SABR imaging follow-up was 24 months (range
5–67 months). Fig. 1 shows representative serial CT images for a
patient without recurrence (Fig. 1A) and a patient with recurrence
(Fig. 1B).
Benign CT imaging features were common, and were identiﬁed
in 89% of all patients (32 of 36 patients). Most common acute be-
nign features were: patchy consolidation (36%) and diffuse consol-
idation (17%); the most common late benign features were
modiﬁed conventional changes (78%). The Supplemental Table (on-
line only) shows the frequency of benign features. The onset of be-
nign features appeared at a median of 6 months after treatment
(range 3–40 months).
High risk CT features were observed in 21 of 36 patients (58%),
most commonly seen as an enlarging opacity (53%), enlarging
opacity after 12 months (44%), cranio-caudal growth (42%) or bulg-
ing margin (39%) (Table 2). All previously published high-risk CT
features included in our study were signiﬁcantly associated with
local recurrence (all p < 0.01, Table 2), and all patients with proven
recurrence had one or more HRFs. Of the three new radiological
features evaluated, only cranio-caudal growth was identiﬁed in
Fig. 1. Representative CT images of patients following SABR with benign and high-risk CT features. New high-risk features (HRFs) noted in each scan speciﬁed. (A) Patient
without local recurrence. A 3 month follow-up scan post-treatment shows diffuse ground glass opacity; a 6 month scan shows a high-risk CT feature: enlarging opacity;
however 12, 24 and 36 month scans all show modiﬁed conventional pattern of late ﬁbrosis with no additional high-risk CT features. No evidence of local recurrence is seen at
3 years post-treatment. (B) Patient with pathology-proven local recurrence. A 6 month follow-up scan shows diffuse consolidation; a 12 month scan shows modiﬁed
conventional pattern of late ﬁbrosis and two high-risk CT features: enlarging opacity and cranio-caudal growth (latter not shown); subsequent scans show additional high-
risk CT features: sequential enlargement, enlarging opacity after 12 months, linear margin disappearance, bulging margin, followed by loss of air bronchogram. Local
recurrence was clinically diagnosed at 22 months and the patient underwent salvage lobectomy at 23 months.
Table 1
Baseline characteristics.
Characteristic All patients (n = 36) Recurrence (n = 12) No-recurrence (n = 24) p-Value
Age – median (range) 68 (57, 86) 65 (60, 86) 69 (57, 82) 0.322
Tumor size mm – mean (SD) 31 (15) 33 (15) 30 (15) 0.561
Male – N (%) 22 (61) 7 (58) 15 (63) 1.00
Charlson score – mean (SD) 2.9 (1.6) 2.9 (1.1) 3.0 (1.9) 0.933
Involved lobe – N (%)
LUL 11 (31) 3 (25) 8 (33) 0.427
LLL 7 (19) 2 (17) 5 (21)
RUL 11 (31) 4 (33) 7 (29)
RML 2 (6) 2 (17) -
RLL 5 (14) 1 (8) 4 (17)
Location – N (%)
Central 12 (33) 4 (33) 8 (33) 1.00
Peripheral 24 (67) 8 (67) 16 (67)
PTV (cm3) – median (min, max) 23 (4, 132) 22 (4, 132) 23 (5, 126) 0.987
RT technique – N (%)
Fixed Beam 28 (78) 9 (75) 19 (79) 1.00
Rapid Arc 8 (22) 3 (25) 5 (21)
Fractionation – N (%)
3 10 (28) 4 (33) 6 (25) 0.738
5 13 (36) 3 (25) 10 (42)
8 13 (36) 5 (42) 8 (33)
Abbreviations: LUL: left upper lobe; LLL: left lower lobe; RUL: right upper lobe; RML: right middle lobe; RLL: right lower lobe; PTV: planning target volume; RT: radiotherapy;
SD: standard deviation.
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speciﬁcity to be clinically useful (p < 0.001). The other two fea-
tures, new axial growth after a complete response, and ratio of cra-
nio-caudal to axial growth, were not adequately sensitive or
speciﬁc for routine clinical use.
The best individual predictor of local recurrence was an enlarg-
ing opacity after 12 months (sensitivity 100%, speciﬁcity 83%;Table 2), with the second-most predictive HRF being cranio-caudal
growth. The latter was the novel HRF identiﬁed in this study (92%
sensitivity, 83% speciﬁcity). Sequential enlargement was 100% spe-
ciﬁc, but had a sensitivity of only 67%.
Table 3 shows the sensitivity and speciﬁcity of detecting recur-
rence based on cumulative number of HRFs on CT imaging. The
presence of P1 HRFs had high sensitivity (100%), however the
Table 2
Frequency of high-risk features.
Characteristic All patients N (%) Rec N (%) No-Rec N (%) p-Value Sens (%) Spec (%) Time (months)a
Any HRF 21 (58) 12 (100) 9 (38) <0.001 100 63 15 (6, 44)
Enlarging opacity 19 (53) 11 (92) 8 (33) <0.001 92 67 15 (6, 44)
Sequential enlargement 8 (22) 8 (67) 0 (0) <0.001 67 100 19 (9, 46)
Enlargement after 12 months 16 (44) 12 (100) 4 (17) <0.001 100 83 22 (12, 44)
Bulging margin 14 (39) 10 (83) 4 (17) <0.001 83 83 22 (6, 44)
Linear Margin disappearance 5 (14) 5 (42) 0 (0) 0.002 42 100 20 (6, 40)
Loss air bronchogram 9 (25) 8 (67) 1 (4) <0.001 67 96 20 (9, 44)
Cranio-Caudal growth 15 (42) 11 (92) 4 (17) <0.001 92 83 13 (6, 44)
Abbreviations: Rec: recurrence; Sens: sensitivity; Spec: speciﬁcity; HRF: high-risk feature.
a median (min, max).
Table 3
Sensitivity and speciﬁcity of CT based on number of high-risk CT features identiﬁed.
Number of HRFs All Patients N (%) Rec N (%) No-Rec N (%) p-Value Sens (%) Spec (%)
P1 21 (58) 12 (100) 9 (38) <0.001 100 63
P2 20 (56) 12 (100) 8 (33) <0.001 100 67
P3 13 (36) 11 (92) 2 (8) <0.001 92 92
P4 12 (33) 10 (83) 2 (8) <0.001 83 92
P5 9 (25) 9 (75) – <0.001 75 100
P6 7 (19) 7 (58) – <0.001 58 100
P7 4 (11) 4 (33) – 0.008 33 100
Odds ratio (95% CI) p-Value
Per each additional HRF 4.01 (2.20, 7.32) <0.001
Abbreviations: Rec: recurrence; Sens: sensitivity; Spec: speciﬁcity; HRF: high-risk feature.
54 Detecting recurrence after lung SABRspeciﬁcity was low (63%), reﬂecting a high false-positive rate with
a low cut-off. With an increasing number of HRFs, the sensitivity
declined while speciﬁcity increased. The presence of P3 features
was very sensitive and speciﬁc (>90%). Each additional HRF identi-
ﬁed resulted in a 4-fold increased odds of recurrence.
The median time from start of SABR to clinical diagnosis of local
recurrence was 22 months (range 6–46 months). In 50% of patients
with recurrences (n = 6), the ﬁrst HRF, in retrospect, appeared
3 months or more before the date of diagnosis of recurrence. In
four patients (33% of recurrences), two or more features were pres-
ent at least 3 months prior to the diagnosis of recurrence. The
appearance of an enlarging opacity and cranio-caudal growth were
the best early indicators of recurrence: each was detected
3 months or more prior to the date of recurrence in 5 patients
(42% of recurrences).
Discussion
Although survival following local recurrence in early-stage
NSCLC is poor, outcomes are signiﬁcantly improved when patients
are able to undergo salvage surgery [19,20]. The American Associ-
ation for Thoracic Surgery has recommended low-dose CT surveil-
lance for surgical patients eligible for subsequent treatment [21].
With surgical salvage and re-irradiation being feasible post-SABR
[22–25], and an increasing proportion of patients undergoing SABR
being otherwise operable [7], the importance of early detection of
local recurrence is increasingly clinically relevant. The present
study validates the clinical utility of previously reported HRFs as
being signiﬁcant predictors of local recurrence. In addition, a novel
HRF has been identiﬁed, the presence of growth in the cranio-cau-
dal direction. Combining these HRFs permits a highly sensitive and
speciﬁc diagnosis of local recurrence without functional imaging.
These ﬁndings are of particular signiﬁcance, since benign CT-fea-
tures occurred almost universally, and often at the same time as
HRFs, yet the HRFs still perform with good sensitivity and speciﬁc-
ity. Finally, the systematic assessment of post-SABR CT images forthese HRFs has the potential to diagnose local recurrence sooner
than achieved otherwise.
The most accurate predictor of local recurrence was an enlarg-
ing opacity after 12 months, however, this criterion inherently can-
not allow for detection of recurrence within the ﬁrst year after
diagnosis. As such, other HRFs must be utilized during the ﬁrst year
post-treatment. These ﬁndings are supported by previous studies
reporting on a combined total of seven histologically conﬁrmed lo-
cal recurrences, which reported that an enlarging mass, particu-
larly after 12 months, being the most sensitive, but not speciﬁc,
feature of recurrence [15,16]. One study reported perfect perfor-
mance for the criteria of three consecutive enlargements (100%
sensitive, 100% speciﬁc) [26]; however, an important limitation
of most studies is the inclusion of patients who had recurrence de-
ﬁned only by CT imaging without biopsy, which risks artiﬁcially
inﬂating the sensitivity and speciﬁcity values. The drawbacks of a
non-systematic approach to diagnosing recurrence is readily evi-
dent, and may lead to resection of ‘recurrences’ without viable tu-
mor cells in one in four patients [15,27]. These ﬁndings underscore
the limitations of current criteria for deﬁning progressive disease
(such as RECIST) and suggest a need for alternative criteria [28].
The novel high-risk CT feature of growth in the cranio-caudal
dimension, has not, to our knowledge, been reported previously.
The biologic basis to this ﬁnding may be that most SABR dose is
deposited in the axial plane, where most ﬁbrosis would also be ex-
pected as there is a clear relationship between dose and CT density
changes [29]. The relatively low amount of low-dose radiation, and
more rapid dose fall-off, in the cranio-caudal direction makes CT
changes in this axis less likely to be related to radiation injury,
and more suggestive of recurrence.
Overall, CT imaging can be very sensitive and also very speciﬁc
for the diagnosis of local recurrence. When two or fewer HRFs are
identiﬁed, speciﬁcity is low. In such patients, PET/CT may be useful
to assist with the diagnosis of local recurrence [30], and also for
ruling out distant recurrence prior to salvage. Employing a
minimum cut-off of 3 or more HRFs identiﬁed, the sensitivity
Fig. 2. Suggested imaging follow-up algorithm for patients following SABR who are candidates for salvage therapy. The reader is referred to reference #11 for a full discussion
of the algorithm. ⁄High-risk CT features include: enlarging opacity, cranio-caudal growth, sequential enlargement, enlarging opacity after 12 months, loss of linear margins,
bulging margin and loss of air bronchograms. ⁄⁄Rule out nodal or distant recurrence prior to salvage.
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salvage treatment may be appropriate, although this ﬁnding
should be validated in other datasets. These sensitivity and speci-
ﬁcity values are promising, since the usual criteria for proceeding
with resection, ﬁne-needle aspiration biopsy (FNAB) or core needle
biopsy (CNB), have performance characteristics in the same range:
sensitivities of 81–91% and 86–97% for FNAB and CNB respectively,
and speciﬁcities of 75–100% and 89–100% respectively [31]. In such
patients with 3 HRFs, omission of PET imaging to assess the pri-
mary lesion may be reasonable, particularly if not readily available
at the treating institution, although it may provide useful informa-
tion regarding the presence or absence of distant disease. An up-
dated follow-up imaging algorithm for patients who are
candidates for salvage therapy for the detection of local recurrence
is provided in Fig. 2, based on a previous systematic review [11].
The management recommendations based on CT imaging pre-
sented herein can serve as a useful tool for clinicians, however, a
multidisciplinary team opinion is preferred whenever possible.
Considerations include risks of diagnostic procedures in frail pa-
tients, which may favor close observation. False-negative or inde-
terminate biopsy results, may favor proceeding directly tosalvage therapy, particularly if the clinical suspicion of recurrence
is high. Additionally, many patients will require close imaging fol-
low-up for an evolving ﬁbrosis for a number of years before a
recurrence can be ruled-out. To address patient concerns, it may
be useful to inform patients prior to SABR about the common
appearance of post-treatment lung changes and their low risk of
cancer recurrence, similar to what patients have found helpful in
the discussion of pulmonary nodules [32].
There are inherent limitations of this study. The study is retro-
spective in nature, and the sample size is modest. The stipulation
that patients with recurrence require pathological proof for inclu-
sion in this study is essential to avoid inﬂating the estimated per-
formance of CT. However, given the excellent local control rates
following SABR, the sample size of this study becomes limited,
and as such these patients were drawn from a large institutional
database (31 recurrences and 507 non-recurrences available, as de-
scribed above). Nevertheless, to our knowledge, this report still
represents the largest study to date detailing the radiographic
appearance of pathology-proven local recurrences after lung
SABR. Assembling a substantially larger dataset of patients
with pathological proof of recurrence would likely require a
56 Detecting recurrence after lung SABRmulti-institutional pooled analysis. Patients without histologic
conﬁrmation of recurrence were not included in our study, since
such patients who are diagnosed based on imaging ﬁndings only
may in fact have benign ﬁbrosis [15]; inclusion of these patients
would overinﬂate the performance of CT imaging. Since patients
who had pathologic proof of recurrence are likely different from
patients who were unable to undergo conﬁrmatory biopsy, this
selection may limit the generalizability of our ﬁndings, including
the performance characteristics of the HRFs, to the latter group.
The clinical impact of this lack of generalizability would likely be
minimal, since patients who are unable to have conﬁrmatory biop-
sies are often unﬁt for surgical salvage. In this study, ‘enlarging
opacity’ was deﬁned on axial slices; in centers with isotropic
reconstructions, deﬁning cranio-caudal growth as a separate risk
factor may be redundant if enlargement is measured in all planes.
Although all measurements were made using lung window/level
settings, standardizing the deﬁnition of ‘opacity’ in terms of HU
density changes may be useful to increase generalizability. In addi-
tion, there may be underlying differences in tumor biology not cap-
tured herein (e.g. volume doubling time) that may help to predict
timing of recurrence.
For ethical reasons, our control patients without recurrence
were not pathologically conﬁrmed, however, they underwent a
minimum follow-up of one year to rule-out local recurrence. We
cannot exclude the possibility that a small number of these control
patients could develop a late recurrence in the future. In addition,
not all of these ‘control’ patients would be expected to have suspi-
cious CT ﬁndings. Since PET/CT was not routinely done on matched
controls, the sensitivity/speciﬁcity of PET/CT could not be evalu-
ated herein, and the role of FDG-PET/CT warrants further investiga-
tion. Finally, there may be variability in the identiﬁcation of HRFs
by physicians, which may be amenable to online training work-
shops; images herein were analyzed by radiation oncologists,
rather than radiologists, as the latter may be unfamiliar with cur-
rent radiation oncology literature regarding HRFs. More detailed
objective measures for the detection of recurrence include CT tex-
ture and volumetric analysis, both of which are currently being
evaluated [33].
In conclusion, as the use of SABR increases in clinical practice,
the need for objective measures to distinguish recurrence from
ﬁbrosis on follow-up imaging is pressing. Several HRFs, including
one novel HRF, have been validated to be predictive of local recur-
rence. A systematic assessment of follow-up CTs for HRFs may al-
low for earlier detection of recurrence. Using a ‘‘high-risk count’’
cut-off of 3 or more features on CT imaging confers excellent sen-
sitivity and speciﬁcity for the detection of local recurrence.
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